Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy among women of reproductive age. PCOS leads to metabolic dysfunction such as dyslipidemia, obesity, and glucose intolerance based on hyperandrogenemia, hyperinsulinemia, and dysregulated adipokine secretion.
Objective: The aim of this study was to investigate whether a new marker, InsuTAG (fasting insulin×fasting triglycerides) could predict insulin resistance (IR) in patients of PCOS.
Methods: In this study, retrospective data of 300 female patients diagnosed with PCOS were analyzed. The relationship between InsuTAG and HOMA-IR, TyG, and TG/HDL-C scores related to insulin resistance was evaluated. In addition, the distribution of the cases according to the cut-off values was determined.
Results: Log-transformed forms of InsuTAG and HOMA-IR, TyG and TG/HDL-C results were positively correlated, respectively. (r = 0.85, p < 0.001; r = 0.78, p < 0.001; r = 0.72, p < 0.001). Sensitivity, specificity, positive predictive value and negative predictive values for InsuTAG were calculated as 85%, 85%, 82% and 88%, respectively.
Conclusion: This study is the first to compare the InsuTAG, another predictor of insulin resistance, with other IR markers in women with PCOS. InsuTAG is a novel biomarker based on plasma sampling of insulin and triglyceride, with minimally invasive, inexpensive and orientally accessible features.
Graphical Abstract
[1]
Broekmans, F.J.; Knauff, E.A.H.; Valkenburg, O.; Laven, J.S.; Eijkemans, M.J.; Fauser, B.C.J.M. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG, 2006, 113(10), 1210-1217.
[http://dx.doi.org/10.1111/j.1471-0528.2006.01008.x] [PMID: 16972863]
[http://dx.doi.org/10.1111/j.1471-0528.2006.01008.x] [PMID: 16972863]
[2]
Carmina, E.; Oberfield, S.E.; Lobo, R.A. The diagnosis of polycystic ovary syndrome in adolescents. Am. J. Obstet. Gynecol., 2010, 203(3), 201.e1-201.e5.
[http://dx.doi.org/10.1016/j.ajog.2010.03.008] [PMID: 20435290]
[http://dx.doi.org/10.1016/j.ajog.2010.03.008] [PMID: 20435290]
[3]
Rostamtabar, M.; Esmaeilzadeh, S.; Tourani, M.; Rahmani, A.; Baee, M.; Shirafkan, F.; Saleki, K.; Mirzababayi, S.S.; Ebrahimpour, S.; Nouri, H.R. Pathophysiological roles of chronic low‐grade inflammation mediators in polycystic ovary syndrome. J. Cell. Physiol., 2021, 236(2), 824-838.
[http://dx.doi.org/10.1002/jcp.29912] [PMID: 32617971]
[http://dx.doi.org/10.1002/jcp.29912] [PMID: 32617971]
[4]
Saltiel, A.R.; Kahn, C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 2001, 414(6865), 799-806.
[http://dx.doi.org/10.1038/414799a] [PMID: 11742412]
[http://dx.doi.org/10.1038/414799a] [PMID: 11742412]
[5]
Sørensen, L.P.; Søndergaard, E.; Nellemann, B.; Christiansen, J.S.; Gormsen, L.C.; Nielsen, S. Increased VLDL-triglyceride secretion precedes impaired control of endogenous glucose production in obese, normoglycemic men. Diabetes, 2011, 60(9), 2257-2264.
[http://dx.doi.org/10.2337/db11-0040] [PMID: 21810597]
[http://dx.doi.org/10.2337/db11-0040] [PMID: 21810597]
[6]
Sparks, J.D.; Sparks, C.E.; Adeli, K. Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol., 2012, 32(9), 2104-2112.
[http://dx.doi.org/10.1161/ATVBAHA.111.241463] [PMID: 22796579]
[http://dx.doi.org/10.1161/ATVBAHA.111.241463] [PMID: 22796579]
[7]
Boucher, J.; Kleinridders, A.; Kahn, C.R. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb. Perspect. Biol., 2014, 6(1), a009191.
[http://dx.doi.org/10.1101/cshperspect.a009191]
[http://dx.doi.org/10.1101/cshperspect.a009191]
[8]
Unluhizarci, K.; Karaca, Z.; Kelestimur, F. Role of insulin and insulin resistance in androgen excess disorders. World J. Diabetes, 2021, 12(5), 616-629.
[http://dx.doi.org/10.4239/wjd.v12.i5.616] [PMID: 33995849]
[http://dx.doi.org/10.4239/wjd.v12.i5.616] [PMID: 33995849]
[9]
DeFronzo, R.A.; Tobin, J.D.; Andres, R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am. J. Physiol., 1979, 237(3), E214-E223.
[PMID: 382871]
[PMID: 382871]
[10]
Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7), 412-419.
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[11]
Kheirollahi, A.; Teimouri, M.; Karimi, M.; Vatannejad, A.; Moradi, N.; Borumandnia, N. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis., 2020, 19(1), 235.
[http://dx.doi.org/10.1186/s12944-020-01410-8]
[http://dx.doi.org/10.1186/s12944-020-01410-8]
[12]
Thota, R.N.; Abbott, K.A.; Ferguson, J.J.A.; Veysey, M.; Lucock, M.; Niblett, S.; King, K.; Garg, M.L. InsuTAG: A novel physiologically relevant predictor for insulin resistance and metabolic syndrome. Sci. Rep., 2017, 7(1), 15204.
[http://dx.doi.org/10.1038/s41598-017-15460-z] [PMID: 29123160]
[http://dx.doi.org/10.1038/s41598-017-15460-z] [PMID: 29123160]
[13]
Vatner, D.F.; Majumdar, S.K.; Kumashiro, N.; Petersen, M.C.; Rahimi, Y.; Gattu, A.K.; Bears, M.; Camporez, J.P.G.; Cline, G.W.; Jurczak, M.J.; Samuel, V.T.; Shulman, G.I. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc. Natl. Acad. Sci. USA, 2015, 112(4), 1143-1148.
[http://dx.doi.org/10.1073/pnas.1423952112] [PMID: 25564660]
[http://dx.doi.org/10.1073/pnas.1423952112] [PMID: 25564660]
[14]
Cerf, M.E. Beta cell dysfunction and insulin resistance. Front. Endocrinol., 2013, 4, 37.
[http://dx.doi.org/10.3389/fendo.2013.00037] [PMID: 23542897]
[http://dx.doi.org/10.3389/fendo.2013.00037] [PMID: 23542897]
[15]
Vine, D.F.; Beilin, L.J.; Burrows, S.; Huang, R.C.; Hickey, M.; Hart, R.; Proctor, S.D.; Mori, T.A. ApoB48-lipoproteins are associated with cardiometabolic risk in adolescents with and without polycystic ovary syndrome. J. Endocr. Soc., 2020, 4(8), bvaa061.
[http://dx.doi.org/10.1210/jendso/bvaa061] [PMID: 32803089]
[http://dx.doi.org/10.1210/jendso/bvaa061] [PMID: 32803089]
[16]
Zheng, S.; Tong, M.; Dong, L.; Du, C.; Zheng, X.; Wang, L.; Huang, P.; Liu, W.; Lin, M.; Liu, C. Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome. Endocr. Connect., 2020, 9(2), 154-162.
[http://dx.doi.org/10.1530/EC-19-0559] [PMID: 31910158]
[http://dx.doi.org/10.1530/EC-19-0559] [PMID: 31910158]
[17]
Talbott, E.; Guzick, D.; Clerici, A.; Berga, S.; Detre, K.; Weimer, K.; Kuller, L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler. Thromb. Vasc. Biol., 1995, 15(7), 821-826.
[http://dx.doi.org/10.1161/01.ATV.15.7.821] [PMID: 7600112]
[http://dx.doi.org/10.1161/01.ATV.15.7.821] [PMID: 7600112]
[18]
Schmidt, J.; Landin-Wilhelmsen, K.; Brännström, M.; Dahlgren, E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year controlled follow-up study. J. Clin. Endocrinol. Metab., 2011, 96(12), 3794-3803.
[http://dx.doi.org/10.1210/jc.2011-1677] [PMID: 21956415]
[http://dx.doi.org/10.1210/jc.2011-1677] [PMID: 21956415]
[19]
Hudecova, M.; Jan, H.; Christian, B.; Poromaa Inger, S. Long-term reproductive and metabolic consequences of PCOS. Curr. Diabetes Rev., 2012, 8(6), 444-451.
[http://dx.doi.org/10.2174/157339912803529913] [PMID: 22934549]
[http://dx.doi.org/10.2174/157339912803529913] [PMID: 22934549]
[20]
Mulder, C.L.; Lassi, Z.S.; Grieger, J.A.; Ali, A.; Jankovic-Karasoulos, T.; Roberts, C.T.; Andraweera, P.H. Cardio‐metabolic risk factors among young infertile women: A systematic review and meta‐analysis. BJOG, 2020, 127(8), 930-939.
[http://dx.doi.org/10.1111/1471-0528.16171] [PMID: 32048421]
[http://dx.doi.org/10.1111/1471-0528.16171] [PMID: 32048421]
[21]
Navaeian, M.; Asadian, S.; Ahmadpour Yazdi, H.; Gheibi, N. ANGPTL8 roles in proliferation, metabolic diseases, hypothyroidism, polycystic ovary syndrome, and signaling pathways. Mol. Biol. Rep., 2021, 48(4), 3719-3731.
[http://dx.doi.org/10.1007/s11033-021-06270-8] [PMID: 33864588]
[http://dx.doi.org/10.1007/s11033-021-06270-8] [PMID: 33864588]
[22]
Cheal, K.L.; Abbasi, F.; Lamendola, C.; McLaughlin, T.; Reaven, G.M.; Ford, E.S. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes, 2004, 53(5), 1195-1200.
[http://dx.doi.org/10.2337/diabetes.53.5.1195] [PMID: 15111486]
[http://dx.doi.org/10.2337/diabetes.53.5.1195] [PMID: 15111486]
[23]
Bray, G.A.; Bellanger, T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocr. J., 2006, 29(1), 109-118.
[http://dx.doi.org/10.1385/ENDO:29:1:109] [PMID: 16622298]
[http://dx.doi.org/10.1385/ENDO:29:1:109] [PMID: 16622298]
[24]
Keskin, M.; Kurtoglu, S.; Kendirci, M.; Atabek, M.E.; Yazici, C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics, 2005, 115(4), e500-e503.
[http://dx.doi.org/10.1542/peds.2004-1921] [PMID: 15741351]
[http://dx.doi.org/10.1542/peds.2004-1921] [PMID: 15741351]
[25]
Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation, 2002, 106(25), 3143-3421.
[http://dx.doi.org/10.1161/circ.106.25.3143] [PMID: 12485966]
[http://dx.doi.org/10.1161/circ.106.25.3143] [PMID: 12485966]
[26]
Butler, A.E.; Abouseif, A.; Dargham, S.R.; Sathyapalan, T.; Atkin, S.L. Metabolic comparison of polycystic ovarian syndrome and control women in Middle Eastern and UK Caucasian populations. Sci. Rep., 2020, 10(1), 18895.
[http://dx.doi.org/10.1038/s41598-020-75109-2] [PMID: 33144665]
[http://dx.doi.org/10.1038/s41598-020-75109-2] [PMID: 33144665]
[27]
Andrisse, S.; Garcia-Reyes, Y.; Pyle, L.; Kelsey, M.M.; Nadeau, K.J.; Cree-Green, M. Racial and ethnic differences in metabolic disease in adolescents with obesity and polycystic ovary syndrome. J. Endocr. Soc., 2021, 5(4), bvab008.
[http://dx.doi.org/10.1210/jendso/bvab008] [PMID: 33644620]
[http://dx.doi.org/10.1210/jendso/bvab008] [PMID: 33644620]
[28]
Vigna, L.; Tirelli, A.S.; Gaggini, M.; Di Piazza, S.; Tomaino, L.; Turolo, S.; Moroncini, G.; Chatzianagnostou, K.; Bamonti, F.; Vassalle, C. Insulin resistance and cardiometabolic indexes: Comparison of concordance in working-age subjects with overweight and obesity. Endocrine, 2022, 77(2), 231-241.
[http://dx.doi.org/10.1007/s12020-022-03087-8] [PMID: 35665880]
[http://dx.doi.org/10.1007/s12020-022-03087-8] [PMID: 35665880]
[29]
Guerrero-Romero, F.; Simental-Mendía, L.E.; González-Ortiz, M.; Martínez-Abundis, E.; Ramos-Zavala, M.G.; Hernández-González, S.O.; Jacques-Camarena, O.; Rodríguez-Morán, M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab., 2010, 95(7), 3347-3351.
[http://dx.doi.org/10.1210/jc.2010-0288] [PMID: 20484475]
[http://dx.doi.org/10.1210/jc.2010-0288] [PMID: 20484475]
[30]
McLaughlin, T.; Abbasi, F.; Cheal, K.; Chu, J.; Lamendola, C.; Reaven, G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann. Intern. Med., 2003, 139(10), 802-809.
[http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00007] [PMID: 14623617]
[http://dx.doi.org/10.7326/0003-4819-139-10-200311180-00007] [PMID: 14623617]
